5FR.F MENICON CO.LTD
- Market cap
- EUR 772M
- P/E
- 19.6x
- P/B
- 1.41x
- ROE
- 9.3%
- Dividend yield
- 1.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 5FR.F undervalued?
Graham number5FR.F trades 10.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MENICON CO.LTD fundamental analysis
No fundamental analysis for MENICON CO.LTD yet.
MENICON CO.LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MENICON CO.LTD
Menicon Co., Ltd. produces and sells contact lenses in Japan and internationally. It operates through Vision Care Business and Others segments. The company offers disposable lenses, MTO specialty lenses, myopia management products, and lens care products. It also engages in the manufacture and sale of medical instruments; sale of medical supplies; research and development of intraocular lenses; healthcare business comprising products utilizing self-assembling peptide gel tec…
Full company profileMENICON CO.LTD financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MENICON CO.LTD annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 100B | 110B | 116B | 121B | 126B | 130B |
| Gross Profit | 52.9B | 58.5B | 61.0B | 65.0B | 67.6B | 70.3B |
| Operating Income | 9.96B | 12.1B | 8.95B | 10.0B | 10.2B | 13.7B |
| EBITDA | - | 19.3B | 15.6B | 18.4B | 20.5B | 14.3B |
| Net Income | 6.48B | 7.38B | 4.54B | 5.60B | 5.92B | 8.92B |
| EPS | 86 | 97 | 60 | 74 | 80 | 120 |
| Balance Sheet | ||||||
| Total Assets | 131B | 153B | 180B | 187B | 195B | 203B |
| Total Liabilities | 63.9B | 77.9B | 98.0B | 101B | 99.5B | 107B |
| Shareholders' Equity | 67.0B | 74.6B | 81.7B | 86.1B | 95.0B | 96.2B |
| Cash & Short-term Investments | 33.0B | 41.2B | 46.9B | 42.0B | 32.6B | 34.1B |
| Cash Flow | ||||||
| Operating Cash Flow | 12.7B | 12.7B | 11.9B | 13.9B | 11.8B | - |
| Capital Expenditure | 15.9B | 13.0B | 21.3B | 17.5B | 16.5B | 0.00 |
| Free Cash Flow | -3.23B | -226M | -9.47B | -3.54B | -4.66B | - |
| Ratios | ||||||
| ROE | 9.7% | 9.9% | 5.6% | 6.5% | 6.2% | 9.3% |
| ROA | 4.9% | 4.8% | 2.5% | 3.0% | 3.0% | 4.4% |
| Net Profit Margin | 6.5% | 6.7% | 3.9% | 4.6% | 4.7% | 6.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MENICON CO.LTD dividends
- Dividend yield
- 1.54%
- Forward dividend
- 0.16 EUR
- Payout ratio
- 36.3%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 2.15B | 29 | 36.3% |
| 2025 | JPY 1.90B | 25 | 34.0% |
| 2024 | JPY 1.90B | 25 | 41.9% |
| 2023 | JPY 1.52B | 20 | 20.6% |
| 2022 | JPY 1.32B | 17 | 20.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Oct 1, 2021.
Who owns MENICON CO.LTD
- Insiders 17.93%
- Institutions 23.82%
- Public & others 58.25%
- Shares outstanding 74.3M
- Free float 59.4M
MENICON CO.LTD company profile
- Company name
- MENICON CO.LTD
- Ticker
- 5FR.F
- ISIN
- JP3921270009
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,493
- Fiscal year end
- March
- Address
- 3-21-19, Aoi, Nagoya, Japan, 460-0006
- Phone
- 81 52 935 1515
- Website
- menicon.com
About MENICON CO.LTD
Menicon Co., Ltd. produces and sells contact lenses in Japan and internationally. It operates through Vision Care Business and Others segments. The company offers disposable lenses, MTO specialty lenses, myopia management products, and lens care products. It also engages in the manufacture and sale of medical instruments; sale of medical supplies; research and development of intraocular lenses; healthcare business comprising products utilizing self-assembling peptide gel technology and bone graft substitute materials; life care business consisting of turf grass for green infrastructure; veterinary medical business, such as the sale of supplements for dogs and cats through animal hospitals and veterinary pharmaceutical wholesalers; and food business, including the sale and import/export of agricultural and marine products. The company sells its products to hospitals, ophthalmological clinics, optical shops, pharmaceutical wholesalers, and distributors. It exports its products to approximately 80 countries. Menicon Co., Ltd. was incorporated in 1943 and is headquartered in Nagoya, Japan.
MENICON CO.LTD management
7- Mr. Koji KawauraRepresentative Executive Officer, President, CEO & Director · born 1969
- Mr. Hideki KogaSenior Executive Officer, Director of Corporate Management Head Office & CFO · born 1969
- Mr. Motonari WatanabeSenior Executive Officer and Director of Manufacturing, R&D Head Office · born 1973
- Mr. Kensuke MurakiSenior Executive Officer & Head of the Miru Mirai Business Management Headquarters · born 1972
- Mr. Kenji TakeshitaSenior Executive Officer & Head of Domestic Sales Management Office · born 1968
- Mr. Nicolaas Johannes Adrianus EngelhartSenior Executive Officer & Director of International Business Head Office · born 1972
- Ms. Oxana PastushenkoChief Executive Officer of EMEA